Anti-CD19 CRT-Cells Effective in CLL
Published: 2017-07-18 |
Author: James Nam, PharmD |
Source: Cancer Therapy Advisor
Evidence published in the Journal of Clinical Oncology demonstrates that anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy is highly effective in treating high-risk patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib.
High-risk patients with CLL are aggressively treated and experience high overall response rates (ORR). Yet these patients have low rates of complete response (CR) and overall survival (OS), and frequently relapse. Previous studies demonstrated that lymphodepletion therapy followed by CD10 CAR-T therapy produces high response rates and durable remissions.
For this study, researchers assigned 24 patients with CLL who failed or progressed after ibrutinib therapy to receive lymphodepletion chemotherapy followed by CAR-T cell doses. The primary outcome was safety and feasibility. The overall response rate was 71% after 4 weeks of CAR-T cell infusion therapy. Reversible cytokine release syndrome was observed in 83% of patients and neurotoxicity was observed in 33% of patients, leading to one death.
Twenty of 24 patients received lymphodepletion therapy and CAR-T cells below or at maximum tolerated dose. Nineteen of these patients had an ORR of 74%. Seventeen patients presented with marrow disease prior to therapy, and 15 had no marrow disease after CAR-T cells as evidenced by flow cytometry.